Hoth Therapeutics highlights obesity and pipeline progress to regulators

Hoth Therapeutics ( (HOTH) ) has issued an update.

On and after January 16, 2026, Hoth Therapeutics plans to use newly prepared presentation materials in meetings with U.S. government officials to highlight its weight loss drug program and broader therapeutics pipeline, underscoring the company’s evolution into a diversified clinical-stage player. The materials outline recent and upcoming milestones, including positive case study data for HT-001 published in September 2024 and interim clinical results expected through early 2026, as well as a defined development path for HT-KIT toward an IND submission targeted for late 2026 and preclinical progress on the VA-partnered obesity candidate HT-VA; collectively, these initiatives signal a push to validate multiple drug candidates, expand into obesity and metabolic health, and potentially enhance Hoth’s regulatory traction and positioning in competitive high-growth therapeutic markets.

The most recent analyst rating on (HOTH) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Hoth Therapeutics stock, see the HOTH Stock Forecast page.

More about Hoth Therapeutics

Hoth Therapeutics is a clinical-stage biopharmaceutical company developing next-generation therapeutics across oncology, neurology, dermatology, inflammation, respiratory disease, and metabolic health, targeting large unmet patient needs and high-value markets. The company advances early-stage drug candidates such as HT-001 for skin toxicity from cancer therapies, HT-KIT for mastocytosis and KIT-driven cancers, HT-ALZ for Alzheimer’s disease, and HT-VA for obesity and metabolic disorders, leveraging partnerships with academic and government institutions and supported by an intellectual property portfolio and access to capital markets expertise.

Average Trading Volume: 333,947

Technical Sentiment Signal: Sell

Current Market Cap: $16.21M

Learn more about HOTH stock on TipRanks’ Stock Analysis page.